Skip to main content
. 2024 Feb 26;31(4):460–468. doi: 10.1038/s41418-024-01272-y

Fig. 2. Patients with baseline and follow-up samples using bespoke ctDNA (RaDaRTM) assay.

Fig. 2

ctDNA circulating tumor DNA, FU follow-up.